Kite Pharma Inc (NASDAQ:KITE) announced upcoming presentations related to KTE-C19, Kite’s lead product candidate, that will take place at the 57th ASH Annual Meeting in Orlando, Florida, December 5-8, 2015. KTE-C19 is an investigational therapy in which a patient’s T cells are genetically engineered to express a chimeric antigen receptor (CAR) designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. Kite recently announced that the ZUMA-1 trial transitioned to the pivotal Phase 2 trial.

“We are encouraged by the preliminary findings seen in Phase 1 of our first company-sponsored trial and look forward to presenting the data in a peer-reviewed setting,” said Dr. Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer of Kite.  “Additional biomarker data to be presented will further the understanding of pharmacodynamic mechanisms of KTE-C19 and the importance of optimizing the conditioning chemotherapy regimen prior to KTE-C19 therapy.”

2015 ASH Annual Meeting Presentations

Title: Pharmacodynamic Profile and Clinical Response in Patients with B-Cell Malignancies of Anti-CD19 CAR T-Cell Therapy

Date: Saturday, December 5, 2015: 5:30 – 7:30 PM Eastern
Session: 801. Gene Therapy and Transfer: Poster I
Abstract number: 2042
Location: Orange County Convention Center, Hall A
Presenter: Adrian Bot, M.D., Ph.D., Kite Pharma, Santa Monica, CA

Title: Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Date: Sunday, December 6, 2015: 6:00 – 8:00 PM Eastern
Session: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster II
Abstract number: 2730
Location:
Orange County Convention Center, Hall A
Presenter:
Sattya S. Neelapu, M.D., The University of Texas MD Anderson Cancer Center, Houston, TX

Title: Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Date: Monday, December 7, 2015: 6:00 – 8:00 PM Eastern
Session: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster III
Abstract number: 3991
Location: Orange County Convention Center, Hall A
Presenter: Frederick L. Locke, M.D., Moffitt Cancer Center, Tampa, FL

Title: Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CAR T Cell Therapy

Date: Monday, December 7, 2015: 6:00 – 8:00 PM Eastern
Session: 801. Gene Therapy and Transfer: Poster III
Abstract number: 4426
Location: Orange County Convention Center, Hall A
Presenter: Adrian Bot, M.D., Ph.D., Kite Pharma, Santa Monica, CA  (Original Source)

Shares of Kite Pharma Inc closed yesterday at $73.12. KITE has a 1-year high of $89.21 and a 1-year low of $37.76. The stock’s 50-day moving average is $64.17 and its 200-day moving average is $61.14.

On the ratings front, Kite Pharma has been the subject of a number of recent research reports. In a report issued on November 2, Cowen analyst Eric Schmidt reiterated a Buy rating on KITE. Separately, on October 20, Maxim Group’s Jason McCarthy maintained a Buy rating on the stock and has a price target of $87.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Eric Schmidt and Jason McCarthy have a total average return of 33.5% and -2.3% respectively. Schmidt has a success rate of 67.1% and is ranked #32 out of 3824 analysts, while McCarthy has a success rate of 45.5% and is ranked #3027.

The street is mostly Bullish on KITE stock. Out of 7 analysts who cover the stock, 6 suggest a Buy rating and one recommends to Hold the stock. The 12-month average price target assigned to the stock is $90.00, which represents a potential upside of 23.1% from where the stock is currently trading.

Kite Pharma Inc is a clinical-stage bio pharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells.